Comparative Pharmacology
Head-to-head clinical analysis: TIBSOVO versus TRABECTEDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIBSOVO versus TRABECTEDIN.
TIBSOVO vs TRABECTEDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isocitrate dehydrogenase-2 (IDH2) inhibitor; targets mutant IDH2 isoforms to reduce 2-hydroxyglutarate (2-HG) levels, promoting myeloid differentiation.
Trabectedin binds to the minor groove of DNA, forming adducts that lead to DNA strand breaks and inhibition of transcription. It also affects the tumor microenvironment by modulating cytokine production and inhibiting activated macrophages.
500 mg orally once daily taken with or without food.
1.5 mg/m² intravenously over 24 hours every 3 weeks.
None Documented
None Documented
Terminal elimination half-life: 50-60 hours, supporting once-daily dosing with steady-state reached in approximately 2 weeks.
Clinical Note
moderateTrabectedin + Digoxin
"Trabectedin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTrabectedin + Digitoxin
"Trabectedin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTrabectedin + Deslanoside
"Trabectedin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTrabectedin + Acetyldigitoxin
"Trabectedin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life ranges from 26 to 40 hours (mean ~33 hours) in patients with normal hepatic function, allowing for a 3-weekly dosing interval.
Primarily hepatic metabolism (CYP3A4) and fecal excretion (77% unchanged and metabolites); renal elimination accounts for <1% of absorbed dose.
Primarily fecal (approximately 58% of administered dose) with minor renal excretion (about 21% as unchanged drug and metabolites). Biliary excretion accounts for a significant portion of elimination via feces.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent